Better Drug Design
Sosei Heptares is a world-leader in stabilizing G Protein-Coupled Receptors (GPCRs). Our patent-protected technologies enable unique structural insights into GPCRs as drug targets. As such, we have the ability and the know-how to design new therapeutic agents with optimized pharmacology using Structure-Based Drug Design (SBDD). Our approach delivers drug candidates with improved physicochemical properties, as well as the potential for enhanced safety and efficacy profiles, and could reduce clinical attrition rates.
In short, it’s just Better Drug Design.
Our success is based on a simple two-fold strategy:
1. We only target well-characterized biomolecular pathways with high degrees of validation – high likelihood of generating a therapeutic benefit
2. We exploit our technology advantage to stabilize GPCRs in desired conformations – enables first-time structural and design insights (SBDD) into one of the deepest pools of drug targets across human diseases
Our unique approach has led to a broad and deep early stage pipeline, with several novel candidates partnered with some of world’s leading pharmaceutical companies.